Efficiency of viferon therapy in infants with acute respiratory virus infection
The impact of VIFERON therapy on clinical, immunological, and virological characteristics was evaluated in 40 children aged 1 month to 3,5 years with acute respiratory virus infection. Study group patients (n=20) received a treatment cycle of VIFERON® in a daily dose of 1 000 000 IU. Comparison grou...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ltd. “The National Academy of Pediatric Science and Innovation”
2016-03-01
|
| Series: | Rossijskij Vestnik Perinatologii i Pediatrii |
| Subjects: | |
| Online Access: | https://www.ped-perinatology.ru/jour/article/view/101 |
| _version_ | 1797875343412953088 |
|---|---|
| author | N. V. Okolysheva L. B. Kisteneva E. N. Vyzhlova V. V. Malinovskaya S. G. Cheshik V. V. Parfenov E. A. Ruzhitskaya A. V. Semenov A. P. Fisenko |
| author_facet | N. V. Okolysheva L. B. Kisteneva E. N. Vyzhlova V. V. Malinovskaya S. G. Cheshik V. V. Parfenov E. A. Ruzhitskaya A. V. Semenov A. P. Fisenko |
| author_sort | N. V. Okolysheva |
| collection | DOAJ |
| description | The impact of VIFERON therapy on clinical, immunological, and virological characteristics was evaluated in 40 children aged 1 month to 3,5 years with acute respiratory virus infection. Study group patients (n=20) received a treatment cycle of VIFERON® in a daily dose of 1 000 000 IU. Comparison group patients (n=20) had symptomatic treatment only. The investigators revealed IgM and IgG antibodies to cytomegalovirus, Epstein—Barr virus, and human herpesvirus 6 and determined herpesvirus DNA in blood, saliva, and urine and respiratory virus DNA/RNA in nasopharyngeal swabs. Flow cytofluorometry was used to study the quantitative composition of lymphocytes with phenotypes CD3+, CD3+4+, CD3+8+, CD3-16+56+, and CD3+CD16+CD56+. The efficiency of VIFERON® therapy was evaluated comparing the results of examinations of the children before and 7 days after treatment. In the study group, the VIFERON® therapy-induced elimination rate for rhinovirus, metapneumovirus, and influenza virus A accounted for 100% and that for respiratory syncytial virus and adenovirus was 87,5 and 66,7%, respectively. In the comparison group, the elimination rate for rhinovirus accounted for 66,7% and that for respiratory syncytial virus and adenoviruses was 0%. The effiacy of VIFERON® against herpesviruses was lower than that against respiratory viruses although Epstein–Barr virus and human herpesvirus 6 eliminations were significantly more frequently noted in the study group patients. In this group, there was accelerated resolution of inflammation, a more pronounced immunotropic effect, including an antiviral effect, than in the comparison group. |
| first_indexed | 2024-04-10T01:46:07Z |
| format | Article |
| id | doaj.art-e379b60bae2647819cabb8ec483ab5d1 |
| institution | Directory Open Access Journal |
| issn | 1027-4065 2500-2228 |
| language | Russian |
| last_indexed | 2024-04-10T01:46:07Z |
| publishDate | 2016-03-01 |
| publisher | Ltd. “The National Academy of Pediatric Science and Innovation” |
| record_format | Article |
| series | Rossijskij Vestnik Perinatologii i Pediatrii |
| spelling | doaj.art-e379b60bae2647819cabb8ec483ab5d12023-03-13T09:12:40ZrusLtd. “The National Academy of Pediatric Science and Innovation”Rossijskij Vestnik Perinatologii i Pediatrii1027-40652500-22282016-03-01602788694Efficiency of viferon therapy in infants with acute respiratory virus infectionN. V. Okolysheva0L. B. Kisteneva1E. N. Vyzhlova2V. V. Malinovskaya3S. G. Cheshik4V. V. Parfenov5E. A. Ruzhitskaya6A. V. Semenov7A. P. Fisenko8ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. Н.Ф. Гамалеи»ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. Н.Ф. Гамалеи»ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. Н.Ф. Гамалеи»ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. Н.Ф. Гамалеи»ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. Н.Ф. Гамалеи»ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. Н.Ф. Гамалеи»Научно-исследовательский клинический институт педиатрии ГБОУ ВПО «РНИМУ им. Н.И. Пирогова»; ГБОУ ВПО «Российский национальный исследовательский медицинский университет» им. Н.И. ПироговаНаучно-исследовательский клинический институт педиатрии ГБОУ ВПО «РНИМУ им. Н.И. Пирогова»; ГБОУ ВПО «Российский национальный исследовательский медицинский университет» им. Н.И. ПироговаЦентральная клиническая больница с поликлиникой Управления делами Президента Российской Федерации, МоскваThe impact of VIFERON therapy on clinical, immunological, and virological characteristics was evaluated in 40 children aged 1 month to 3,5 years with acute respiratory virus infection. Study group patients (n=20) received a treatment cycle of VIFERON® in a daily dose of 1 000 000 IU. Comparison group patients (n=20) had symptomatic treatment only. The investigators revealed IgM and IgG antibodies to cytomegalovirus, Epstein—Barr virus, and human herpesvirus 6 and determined herpesvirus DNA in blood, saliva, and urine and respiratory virus DNA/RNA in nasopharyngeal swabs. Flow cytofluorometry was used to study the quantitative composition of lymphocytes with phenotypes CD3+, CD3+4+, CD3+8+, CD3-16+56+, and CD3+CD16+CD56+. The efficiency of VIFERON® therapy was evaluated comparing the results of examinations of the children before and 7 days after treatment. In the study group, the VIFERON® therapy-induced elimination rate for rhinovirus, metapneumovirus, and influenza virus A accounted for 100% and that for respiratory syncytial virus and adenovirus was 87,5 and 66,7%, respectively. In the comparison group, the elimination rate for rhinovirus accounted for 66,7% and that for respiratory syncytial virus and adenoviruses was 0%. The effiacy of VIFERON® against herpesviruses was lower than that against respiratory viruses although Epstein–Barr virus and human herpesvirus 6 eliminations were significantly more frequently noted in the study group patients. In this group, there was accelerated resolution of inflammation, a more pronounced immunotropic effect, including an antiviral effect, than in the comparison group.https://www.ped-perinatology.ru/jour/article/view/101детиострые респираторные вирусные инфекции герпесвирусыклеточный иммунитетвиферон® |
| spellingShingle | N. V. Okolysheva L. B. Kisteneva E. N. Vyzhlova V. V. Malinovskaya S. G. Cheshik V. V. Parfenov E. A. Ruzhitskaya A. V. Semenov A. P. Fisenko Efficiency of viferon therapy in infants with acute respiratory virus infection Rossijskij Vestnik Perinatologii i Pediatrii дети острые респираторные вирусные инфекции герпесвирусы клеточный иммунитет виферон® |
| title | Efficiency of viferon therapy in infants with acute respiratory virus infection |
| title_full | Efficiency of viferon therapy in infants with acute respiratory virus infection |
| title_fullStr | Efficiency of viferon therapy in infants with acute respiratory virus infection |
| title_full_unstemmed | Efficiency of viferon therapy in infants with acute respiratory virus infection |
| title_short | Efficiency of viferon therapy in infants with acute respiratory virus infection |
| title_sort | efficiency of viferon therapy in infants with acute respiratory virus infection |
| topic | дети острые респираторные вирусные инфекции герпесвирусы клеточный иммунитет виферон® |
| url | https://www.ped-perinatology.ru/jour/article/view/101 |
| work_keys_str_mv | AT nvokolysheva efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT lbkisteneva efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT envyzhlova efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT vvmalinovskaya efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT sgcheshik efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT vvparfenov efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT earuzhitskaya efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT avsemenov efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection AT apfisenko efficiencyofviferontherapyininfantswithacuterespiratoryvirusinfection |